Akdaş A, Simşek F, Ilker Y, Türkeri L, Ercan H
Department of Urology, Marmara University, School of Medicine, Istanbul, Turkey.
Int Urol Nephrol. 1993;25(3):271-8.
The value of prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) as serum markers in carcinoma of the prostate (CaP) was investigated in this study. A group of 75 patients entered this trial, 25 with CaP, 25 with benign prostatic hyperplasia (BPH) and 25 with urologic disorders other than prostatic diseases. In the CaP group, PAP was above normal levels in 48% of the patients and PSA in 92%. In the BPH group these rates were 20% and 72%, respectively. No elevation was detected in the third group. In CaP patients with capsular invasion, PAP and PSA levels were above normal in 25 and 87.5%. In metastatic carcinoma, PAP was high in 75% and PSA in 100%. Our study reveals that neither of these markers is useful in the initial diagnosis of CaP. Though PSA seems to be more sensitive, it is not more specific than PAP.
本研究对前列腺癌（CaP）中前列腺酸性磷酸酶（PAP）和前列腺特异性抗原（PSA）作为血清标志物的价值进行了调查。一组75名患者进入该试验，其中25例患有CaP，25例患有良性前列腺增生（BPH），25例患有前列腺疾病以外的泌尿系统疾病。在CaP组中，48%的患者PAP高于正常水平，92%的患者PSA高于正常水平。在BPH组中，这些比率分别为20%和72%。第三组未检测到升高。在有包膜侵犯的CaP患者中，25%的患者PAP水平高于正常，87.5%的患者PSA水平高于正常。在转移性癌中，75%的患者PAP升高，100%的患者PSA升高。我们的研究表明，这些标志物在CaP的初始诊断中均无用处。虽然PSA似乎更敏感，但它并不比PAP更具特异性。
